Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report

Liming Wang, Haijie Ji, Jianjun Zhou, Jiang Xie, Zhanqiang Zhong, Ming Li, Wen Bai, Na Li, Zijia Zhang, Xuejun Wang, Delin Zhu, Yongjun Liu, Mingyuan Wu, Liming Wang, Haijie Ji, Jianjun Zhou, Jiang Xie, Zhanqiang Zhong, Ming Li, Wen Bai, Na Li, Zijia Zhang, Xuejun Wang, Delin Zhu, Yongjun Liu, Mingyuan Wu

Abstract

Cerebral palsy is the most common motor disability in childhood. In current paper, we first report our clinical data regarding administration of umbilical cord mesenchymal stem cells (MSCs) transplantation in treatment of cerebral palsy. A 5-year-old girl with cerebral palsy was treated with multiple times of intravenous and intrathecal administration of MSCs derived from her young sister and was followed up for 28 months. The gross motor dysfunction was improved. Other benefits included enhanced immunity, increased physical strength, and adjusted speech and comprehension. Temporary low-grade fever was the only side effect during the treatment. MSCs may be a safe and effective therapy to improve symptoms in children with cerebral palsy.

References

    1. Bax M, Goldstein M, Rosenbaun P, et al. Proposed definition and classification of cerebral palsy. Developmental Medicine and Child Neurology. 2005;47(8):571–576.
    1. Shevell MI, Majnemer A, Morin I. Etiologic yield of cerebral palsy: a contemporary case series. Pediatric Neurology. 2003;28(5):352–359.
    1. Koman LA, Smith BP, Shilt JS. Cerebral palsy. The Lancet. 2004;363(9421):1619–1631.
    1. Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Devlopmental Medicine Child and Neurology. 2007;109:8–14.
    1. Shevell MI. Current understandings and challenges in the management of cerebral palsy. Minerva Pediatrica. 2009;61(4):399–413.
    1. Shevell M, Miller SP, Scherer SW, Yager JY, Fehlings MG. The Cerebral Palsy Demonstration Project: a multidimensional research approach to cerebral palsy. Seminars in Pediatric Neurology. 2011;18(1):31–39.
    1. Titomanlio L, Kavelaars A, Dalous J, et al. Stem cell therapy for neonatal brain injury: perspectives and challenges. Annals of Neurology. 2011;70(5):698–712.
    1. Friedenstein AJ, Gorskaja UF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Experimental Hematology. 1976;4(5):267–274.
    1. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393–395.
    1. Kang KS, Kim SW, Oh YH, et al. A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study. Cytotherapy. 2005;7(4):368–373.
    1. Ichim TE, Solano F, Lara F, et al. Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report. International Archives of Medicine. 2010;3(1, article 30)
    1. Han H, Chang SK, Chang JJ, Hwang SH, Han SH, Chun BH. Intrathecal injection of human umbilical cord blood-derived mesenchymal stem cells for the treatment of basilar artery dissection: a case report. Journal of Medical Case Reports. 2011;5, article 562
    1. Purandare C, Shitole DG, Belle V, Kedari A, Bora N, Joshi M. Therapeutic potential of autologous stem cell transplantation for cerebral palsy. Case Reports in Transplantation. 2012;2012:6 pages.825289
    1. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91(8):1017–1026.
    1. Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H. Subarachnoid placement of stem cells in neurological disorders. Transplantation Proceedings. 2008;40(4):1145–1147.
    1. Park KI, Teng YD, Snyder EY. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nature Biotechnology. 2002;20(11):1111–1117.
    1. Snyder EY, Yoon C, Flax JD, Macklis JD. Multipotent neural precursors can differentiate toward replacement of neurons undergoing targeted apoptotic degeneration in adult mouse neocortex. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(21):11663–11668.
    1. Goldstein M. The treatment of cerebral palsy: what we know, what we don’t know. Journal of Pediatrics. 2004;145(supplement 2):S42–S46.
    1. Lin YC, Ko TL, Shih YH, et al. Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke. 2011;42(7):2045–2053.
    1. Zhang MJ, Sun JJ, Qian L, et al. Human umbilical mesenchymal stem cells enhance the expression of neurotrophic factors and protect ataxic mice. Brain Research. 2011;1402:122–131.
    1. Bae KS, Park JB, Kim HS, Kim DS, Park DJ, Kang SJ. Neuron-like differentiation of bone marrow-derived mesenchymal stem cells. Yonsei Medical Journal. 2011;52(3):401–412.
    1. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54–63.
    1. Wang H, Wu M, Liu Y. Are mesenchymal stem cells major sources of safe signals in immune system? Cell Immunology. 2012;272(2):112–116.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다